Teplizumab, an anti-CD3 monoclonal antibody, currently the sole licensed immunotherapy for delaying the onset of T1D in the USA (75) acts via inhibition of CD3 activation during TCR signaling, leading to modification of T cell subset abundance and the partial exhaustion of CD8+ T cells (65). This evidence concerns the gene CD8A and type 1 diabetes mellitus.